SEC Info - Healthtech Solutions, Inc./UT

i 0001307624 i false i Q3 i 2022 i --12-31 i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i 0001307624 2022-01-01 2022-09-30 0001307624 2022-11-23 0001307624 2022-09-30 0001307624 2021-12-31 0001307624 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001307624 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001307624 2022-07-01 2022-09-30 0001307624 2021-07-01 2021-09-30 0001307624 2021-01-01 2021-09-30 0001307624 us-gaap:CommonStockMember 2020-12-31 0001307624 hltt:PreferredStockSeriesAMember 2020-12-31 0001307624 hltt:PreferredStockSeriesCMember 2020-12-31 0001307624 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001307624 us-gaap:RetainedEarningsMember 2020-12-31 0001307624 us-gaap:NoncontrollingInterestMember 2020-12-31 0001307624 2020-12-31 0001307624 us-gaap:CommonStockMember 2021-03-31 0001307624 hltt:PreferredStockSeriesAMember 2021-03-31 0001307624 hltt:PreferredStockSeriesCMember 2021-03-31 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001307624 us-gaap:RetainedEarningsMember 2021-03-31 0001307624 us-gaap:NoncontrollingInterestMember 2021-03-31 0001307624 2021-03-31 0001307624 us-gaap:CommonStockMember 2021-06-30 0001307624 hltt:PreferredStockSeriesAMember 2021-06-30 0001307624 hltt:PreferredStockSeriesCMember 2021-06-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001307624 us-gaap:RetainedEarningsMember 2021-06-30 0001307624 us-gaap:NoncontrollingInterestMember 2021-06-30 0001307624 2021-06-30 0001307624 us-gaap:CommonStockMember 2021-12-31 0001307624 hltt:PreferredStockSeriesAMember 2021-12-31 0001307624 hltt:PreferredStockSeriesCMember 2021-12-31 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001307624 us-gaap:RetainedEarningsMember 2021-12-31 0001307624 us-gaap:NoncontrollingInterestMember 2021-12-31 0001307624 us-gaap:CommonStockMember 2022-03-31 0001307624 hltt:PreferredStockSeriesAMember 2022-03-31 0001307624 hltt:PreferredStockSeriesCMember 2022-03-31 0001307624 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001307624 us-gaap:RetainedEarningsMember 2022-03-31 0001307624 us-gaap:NoncontrollingInterestMember 2022-03-31 0001307624 2022-03-31 0001307624 us-gaap:CommonStockMember 2022-06-30 0001307624 hltt:PreferredStockSeriesAMember 2022-06-30 0001307624 hltt:PreferredStockSeriesCMember 2022-06-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001307624 us-gaap:RetainedEarningsMember 2022-06-30 0001307624 us-gaap:NoncontrollingInterestMember 2022-06-30 0001307624 2022-06-30 0001307624 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001307624 hltt:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001307624 hltt:PreferredStockSeriesCMember 2021-01-01 2021-03-31 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001307624 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001307624 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001307624 2021-01-01 2021-03-31 0001307624 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001307624 hltt:PreferredStockSeriesAMember 2021-04-01 2021-06-30 0001307624 hltt:PreferredStockSeriesCMember 2021-04-01 2021-06-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001307624 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001307624 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001307624 2021-04-01 2021-06-30 0001307624 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001307624 hltt:PreferredStockSeriesAMember 2021-07-01 2021-09-30 0001307624 hltt:PreferredStockSeriesCMember 2021-07-01 2021-09-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001307624 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001307624 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001307624 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001307624 hltt:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001307624 hltt:PreferredStockSeriesCMember 2022-01-01 2022-03-31 0001307624 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001307624 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001307624 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001307624 2022-01-01 2022-03-31 0001307624 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001307624 hltt:PreferredStockSeriesAMember 2022-04-01 2022-06-30 0001307624 hltt:PreferredStockSeriesCMember 2022-04-01 2022-06-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001307624 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001307624 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001307624 2022-04-01 2022-06-30 0001307624 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001307624 hltt:PreferredStockSeriesAMember 2022-07-01 2022-09-30 0001307624 hltt:PreferredStockSeriesCMember 2022-07-01 2022-09-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001307624 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001307624 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001307624 us-gaap:CommonStockMember 2021-09-30 0001307624 hltt:PreferredStockSeriesAMember 2021-09-30 0001307624 hltt:PreferredStockSeriesCMember 2021-09-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001307624 us-gaap:RetainedEarningsMember 2021-09-30 0001307624 us-gaap:NoncontrollingInterestMember 2021-09-30 0001307624 2021-09-30 0001307624 us-gaap:CommonStockMember 2022-09-30 0001307624 hltt:PreferredStockSeriesAMember 2022-09-30 0001307624 hltt:PreferredStockSeriesCMember 2022-09-30 0001307624 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001307624 us-gaap:RetainedEarningsMember 2022-09-30 0001307624 us-gaap:NoncontrollingInterestMember 2022-09-30 0001307624 hltt:ExchangeAgreementMember 2020-11-11 2020-11-12 0001307624 hltt:AssetPurchaseAgreementMember 2022-01-31 0001307624 us-gaap:PatentsMember 2022-07-01 2022-09-30 0001307624 us-gaap:PatentsMember 2022-01-01 2022-09-30 0001307624 us-gaap:FiniteLivedIntangibleAssetsMember 2022-07-01 2022-09-30 0001307624 us-gaap:FiniteLivedIntangibleAssetsMember 2022-01-01 2022-09-30 0001307624 us-gaap:FiniteLivedIntangibleAssetsMember 2021-07-01 2021-09-30 0001307624 us-gaap:FiniteLivedIntangibleAssetsMember 2021-01-01 2021-09-30 0001307624 hltt:HealthtechSolutionsMember hltt:SeriesCPreferredStocksMember 2021-05-01 2021-05-07 0001307624 hltt:VarianBiopharmaceuticalIncMember 2022-09-30 0001307624 hltt:AssetPurchaseAgreementMember 2022-01-01 2022-01-31 0001307624 hltt:PredictiveTechnologyGroupMember 2022-01-31 0001307624 hltt:StormFundingLLCMember hltt:MayTwoThousandTwentyMember hltt:DavidRubinMember 2022-01-01 2022-09-30 0001307624 hltt:EProdigyFinancialLLCMember hltt:MrRubinMember 2022-09-30 0001307624 hltt:EProdigyFinancialLLCMember hltt:StormFundingLLCMember 2022-09-30 0001307624 hltt:EProdigyFinancialLLCMember hltt:MrRubinMember 2022-01-01 2022-09-30 0001307624 hltt:EProdigyFinancialLLCMember hltt:StormFundingLLCMember 2022-01-01 2022-09-30 0001307624 hltt:DenisKleinfeldMember hltt:AdvisoryAgreementMember 2022-01-01 2022-09-30 0001307624 hltt:DenisKleinfeldMember hltt:AdvisoryAgreementMember 2021-01-01 2021-12-31 0001307624 hltt:MediScanMember 2022-09-01 2022-09-13 0001307624 2022-09-01 2022-09-06 0001307624 hltt:UndesignatedPreferredStockMember 2022-09-30 0001307624 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-09-30 0001307624 hltt:ThreeIndividualsMember 2022-09-01 2022-09-06 0001307624 hltt:ThreeIndividualsMember 2022-09-06 0001307624 hltt:TwoEntitiesMember 2022-09-01 2022-09-13 0001307624 hltt:MediScanMember 2022-09-13 0001307624 hltt:MediScanMember 2022-01-01 2022-09-30 0001307624 us-gaap:ConvertibleNotesPayableMember 2020-08-01 2020-09-30 0001307624 us-gaap:ConvertibleNotesPayableMember 2020-11-01 2020-11-30 0001307624 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001307624 us-gaap:ConvertibleNotesPayableMember 2022-05-01 2022-05-06 0001307624 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-01-01 2022-09-30 0001307624 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2020-01-01 2020-12-31 0001307624 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-01-01 2021-03-31 0001307624 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-01-01 2021-05-06 0001307624 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-04-01 2021-06-30 0001307624 hltt:MediScanMember 2021-01-01 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

i ☑ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

i ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. i Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) i Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check One)

Large accelerated filer ☐ Accelerated filer ☐ i Non-accelerated filer ☑ Smaller reporting company i ☐ Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ i No☑

APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date:

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

At the end of January 2022 we acquired from Predictive Biotech, Inc. all of the assets related to its business of developing and producing wound care treatments, including a placental membrane allograft designed to act as a covering or barrier for the protection of burns and non-healing wounds such as diabetic foot ulcers. Since acquiring those assets in our newly organized subsidiary, Healthtech Wound Care, Inc. (“HWC”), we have focused our immediate attention on achieving the regulatory approvals necessary for HWC to bring its allografts to market and initiating the marketing of our allografts. $1,391,194 (i.e. 96%) of the $1,448,596 that we devoted to research and development during the first nine months of 2022 was attributable to efforts of HWC to complete and test a market-ready version of its allograft.

Sales of our wound care allografts commenced in September 2022, as we delivered allografts to five customers for an aggregate purchase price, net of discounts, of $776,221. Payments for the sales did not commence until October, so we recorded accounts receivable from the sales of $720,777, representing the net sales revenue less an allowance for doubtful accounts of $55,444. After recording $51,834 in cost of goods sold (i.e. proportionate allocation to the products sold of the direct costs attributable to their production), we recorded gross profit of $720,175 for the three and nine months ended September 30, 2022. We expect that in future periods our gross margin ratio will be lower than the ratio we recorded in the periods ended September 30, 2022.

The cost of our operations is primarily classified as general and administrative, which totaled $1,113,908 (including $82,500 payable to related parties) during the quarter ended September 30, 2022 and $1,844,649 (Including $172,500 payable to related parties) during the nine months ended September 30, 2022. These expenses primarily involve insurance premiums, office expenses, legal and accounting expenses, compensation of consultants, and other expenses incurred in developing Healthtech Solutions into a viable incubator of development stage medical companies. In total, our operating expenses for the three and nine months ended September 30, 2022 were $1,569,308 and $3,350,452, respectively, resulting in net loss of $844,921 for the three months ended September 30, 2022 and $2,626,066 for the nine months ended September 30, 2022.

We expect that the manufacture and sale of allografts by HWC will become profitable in the foreseeable future. Our business plan, however, contemplates a breadth of operations in addition to wound care treatments. For that reason, our research and development expenses will rise significantly if we obtain the capital resources necessary to fully implement our business plan. In particular, expansion of the operations of HWC to include additional product lines and the effort to bring MediScan’s and RevHeart’s technology to market will require several million dollars of capital expense. For that reason, we cannot predict when we will achieve company-wide profitability.

Our loss from operations during the first nine months of 2021 was $2,973,242, the largest portion of which was related to the market value of common stock that we granted to attract management, research and development expertise and other individuals qualified to aid our projects. Of the $2,973,242 in operating expenses incurred during the nine months ended September 30, 2021, stock compensation represented $1,029,028 of the expense.

In the fall of 2020, prior to the reverse merger of Healthtech Solutions into MediScan, MediScan sold 7% Convertible Debentures to obtain capital. In connection with the reverse merger, the MediScan debentures were exchanged for 7% Convertible Debentures issued by Healthtech Solutions. Healthtech Solutions then sold additional Debentures, with the result that by during the first nine months of 2021 the greater portion of our net loss reflected “other expenses” related to the convertible debentures. In particular, during the six months ended June 30,2021, we incurred items of Other Expenses that added $3,300,879 to our net loss, specifically:

We accounted for our convertible debt in accordance with ASC 815, Derivatives and Hedging as the conversion feature embedded in the convertible debentures could have resulted in the debenture principal and related accrued interest being converted to a variable number of our common shares. The conversion feature on these debentures was variable and based on trailing market prices. It therefore contained an embedded derivative. The fair value of the conversion feature was calculated when the debentures were issued, and we recorded a debenture discount and derivative liability for the calculated value. We recognized interest expense for accretion of the debenture discount over the term of the note. The conversion liability was valued at the end of the reporting period and resulted in income for the reduction in fair value. Among the reasons why we negotiated a cancellation of the Debentures in exchange for common stock was that the volatile price of our stock meant that the gain or loss realized due to the Debentures could often be material to our results.

After taking Other Expenses into account, Healthtech Solutions realized a net loss of $844,921 ($0.01 per share) in the three months ended September 30, 2022. However, 30% of HWC and 18.75% of Medi-Scan were owned by minority investors during that period. Therefore, $105,398 of the net loss contributed by HWC and $3,448 of the net loss contributed by Medi-Scan during the three months ended September 30, 2022 were attributable to those minority interests. These are recorded on our Statement of Operations as “net loss attributable to non-controlling interest.” The remainder, the “net loss attributable to controlling interest”, was $736,075 for the three months ended September 30, 2022.

For the same reason, $448,473 of the net loss realized during the nine months ended September 30, 2022 was attributed to the minority interests, leaving a net loss of $2,177,592 attributable to the controlling interest.

For the three and nine months ended September 30, 2021, the net loss attributable to controlling interest was $1,201,764 and $6,269,511, respectively.

Our company is designed to function as an incubator for development stage medical technology enterprises. During 2021 and 2020 our statements of cash flows reflected that design: in each year we raised capital from the sale of securities and used approximately the amount of cash raised to fund medical research. Our administrative expenses, albeit representing a large portion of our loss in each year, were primarily paid for by issuance of common stock.

During the first nine months of 2022 we modified the funding process. For the funds needed to sustain our operations in the first nine months of 2022, particularly the funds required by HWC to complete development of its allografts and bring them to market, we relied on loans from shareholders and from non-affiliated parties. During those nine months, we borrowed $1,024,631 from shareholders and $1,146,000 from non-affiliated parties.

In the first quarter of 2022, from the loans received from shareholders and non-affiliated parties, we advanced $349,432 to Predictive Biotech, Inc. and its parent as a prepayment of future commissions pursuant to the terms under which we purchased their wound care business. We also reclassified to prepaid commissions a loan of $168,000 that we made to Predictive Biotech, Inc. in December 2021. (Because two of our five customers during the third quarter of 2022 are commissionable to Predictive Biotech, Inc., we amortized $116,000 of the prepaid commissions in that quarter.) The remainder of the loan proceeds funded the net cash that we used in our operating activities during the first nine months of 2022.

In the first nine months of 2021, our sources and uses of funds differed somewhat from the first nine months of 2022. We entered 2021 with $128,996 in the bank (proceeds from the sale of convertible debentures). We added to that $1,792,500 proceeds from the sale of our common stock, $50,000 in debenture proceeds and $121,084 in proceeds of the initial loans from shareholders. That combination enabled us to fund the $1,570,582 that we used in operating activities and the $437,055 that we contributed to the operations of Varian while it was our subsidiary.

At December 31, 2021 Healthtech Solutions had a working capital deficit of $757,563. During the first nine months of 2022, we increased the working capital deficit by $1,970,294 to $2,727,857. The increase in the working capital deficit occurred primarily because we borrowed funds on a short-term basis and used the funds to pay our present expenses and prepay future expenses.

We expect HWC’s wound care business to become profitable during the fourth quarter of 2022, which will alleviate some of the cash flow burden of that business. That revenue, occurring shortly after our acquisition of the wound care business, will likely be the exception to the norm for our portfolio companies. Our business plan contemplates that, to attract exciting additions to our portfolio, we will offer most the several million dollars of financing that is necessary to bring a medical technology to a stage where its sponsor can function independently. Since our ambition is to sustain a portfolio of such enterprises, our near term capital requirements (near term being the two to three years before we can anticipate initial returns on most of our investments) will be tens of millions of dollars.

Note 3 to our consolidated financial statements discloses that the financial condition of Healthtech Solutions raises substantial doubt as to the Company's ability to continue as a going concern. Management intends to pursue one or more offerings of securities in order to obtain the funds that will be necessary for successful implementation of our business plan. At present, however, no commitments for future funding have been received.

In preparing our financial statements we are required to formulate working policies regarding valuation of our assets and liabilities and to develop estimates of those values. In our preparation of the financial statements for the three and nine month periods ended September 30, 2022, there were three estimates made which were (a) subject to a high degree of uncertainty and (b) material to our results. These were:

There were no recent accounting pronouncements that have or will have a material effect on the Corporation’s financial position or results of operations.

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition or results of operations.

Evaluation of Disclosure Controls and Procedures. As of September 30, 2022, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures have the following material weaknesses:

● Substantial portions of our accounting functions are outsourced, thus reducing the ability of senior management to supervise those functions.

● The relatively small number of our employees who are responsible for accounting functions prevents us from segregating duties within our internal control system.

● Our internal financial staff lack expertise in identifying and addressing complex accounting issues under U.S. Generally Accepted Accounting Principles.

● We have not developed sufficient documentation concerning our existing financial processes, risk assessment and internal controls.

Based on his evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s system of disclosure controls and procedures was not effective as of September 30, 2022 for the purposes described in this paragraph.

Changes in Internal Controls. There was no change in internal control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Securities Exchange Act or 1934) identified in connection with the evaluation described above that occurred during Healthtech Solutions' third fiscal quarter that has materially affected or is reasonably likely to materially affect Healthtech Solutions' internal control over financial reporting.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	i HEALTHTECH SOLUTIONS, INC./UT
	(Exact Name of Registrant in its Charter)

i Utah		i 84-2528660
(State or Other Jurisdiction of incorporation or organization)		(I.R.S. Employer I.D. No.)

	i 181 Dante Avenue, i Tuckahoe, i NY i 10707
	(Address of Principal Executive Offices)
	Issuer’s Telephone Number: i 844- i 926-3399
	(Registrant's telephone number, including area code)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	Not Applicable

*Part I. Financial Information*		*Page No.*

Item 1.	Financial Statements (unaudited):	F-1

	Consolidated Balance Sheets (Unaudited) – September 30, 2022 and December 31, 2021	F-1

	Consolidated Statements of Operations (Unaudited) - for the Three and Nine Months Ended September 30, 2022 and 2021	F-2

	Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) for the Three and Nine Months Ended September 30, 2022 and 2021	F-3

	Statements of Cash Flows (Unaudited) – for the Nine Months Ended September 30, 2022 and 2021	F-4

	Notes to Consolidated Financial Statements (Unaudited)	F-5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3

Item 4.	Controls and Procedures	3

*Part II. Other Information*

Item 1.	Legal Proceedings	4

Item 1A.	Risk Factors	4

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	4

Item 3.	Defaults Upon Senior Securities	4

Item 4.	Mine Safety Disclosures	5

Item 5.	Other Information	5

Item 6.	Exhibits	5

	Signatures	5


	September 30, 2022			December 31, 2021
Current Assets:
Cash	$	i 192,006		$	i 7,105
Accounts receivable		i 720,777			—
Inventory		i 198,535			—
Prepaid expenses		i 211,947			i 137,997
Loan receivable		—			i 168,000
Other receivable		i 3,970			—
Total Current Assets		i 1,327,235			i 313,102
Long Term Assets:
Investment in and advance to non-consolidated affiliate		i 110,000			i 110,000
Fixed Assets acquired net of accumulated depreciation		i 93,333			—
Intangible assets net of accumulated amortization		i 106,892			—
Total Long Term Assets		i 310,225			i 110,000

Total Assets	$	i 1,637,460		$	i 423,102

Current Liabilities:
Accounts payable and accrued expenses	$	i 1,981,036		$	i 733,743
Loans from non-affiliated parties		i 1,146,000			—
Loans from shareholders		i 1,361,552			i 336,921
Total Current Liabilities		i 4,488,588			i 1,070,665

Total Liabilities		i 4,488,588			i 1,070,665

Stockholders' Equity (Deficit):
Series A preferred stock, $ i i 0.001 / par value, i i 2,000,000 / authorized, i i 110,520 / and i i 156,837 / issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		i 110			i 110
Common stock, $ i i 0.001 / par value, i i 200,000,000 / shares authorized, i i i i 69,965,933 / / / issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		i 69,966			i 66,966
Additional paid-in capital		i 10,252,786			i 9,833,286
Accumulated deficit		( i 12,662,603	)		( i 10,547,924	)
Stockholders' Equity (Deficit) Attributable to the Company:		( i 2,339,741	)		( i 647,563	)
Non controlling Interest		( i 511,387	)		—
Total Stockholders' Equity (Deficit)		( i 2,851,128	)		( i 647,563	)

Total Liabilities and Stockholders' Equity (Deficit)	$	i 1,637,460		$	i 423,102

See notes to consolidated financial statements.


		For the Nine Months Ended
		September 30, 2022			September 30, 2021

Cash flows from operating activities
Net loss	$	( i 2,626,066	)	$	( i 6,274,121	)
Adjustments to Reconcile Net Loss to Net Cash used in operating activities:
Amortization expense		i 30,540			i 25,926
Depreciation expense		i 26,667
Amortization of discount on convertible debenture		—			i 351,212
Non-cash compensation		i 100,000
Non-cash stock option expense		i 135,000
Stock compensation expense		—			i 1,029,028
Inventory reserve		i 22,178			—
Allowance for bad debt		i 55,444			—
Non-cash interest expense		—			i 15,871
Change in fair value of derivative liabilities		—			i 2,933,735
Changes in operating assets and liabilities:
Prepaid expenses		i 103,260			( i 71,460	)
Prepaid commissions		( i 266,642	)		—
Inventory		( i 220,713	)		—
Accounts receivable		( i 776,221	)		—
Other payable		( i 3,970	)		—
Accounts payable and accrued expenses		i 1,434,793			i 419,227
Net cash used in operating activities		( i 1,985,730	)		( i 1,570,582	)

Cash flows from investing activities:
Cash paid for purchase of Varian, net of cash acquired		—			( i 437,055	)
Net cash used in investing activities		—			( i 437,055	)

Cash flows from financing activities:
Proceeds of loans from shareholders		i 1,024,631			i 121,084
Proceeds from convertible debenture		—			i 50,000
Settlement of loan from shareholder		—			( i 50,542	)
Loans from non-affiliated parties		i 1,146,000			—
Capital contributions		i —			i 4,558
Issuance of common stock					i 1,792,500
Net cash provided by financing activities		i 2,170,631			i 1,917,600

Net increase (decrease) in cash		i 184,901			( i 90,037	)
Cash, beginning of period		i 7,105			i 128,996
Cash, end of period	$	i 192,006		$	i 38,959

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$	—		$	i 61
Cash paid for taxes	$	—		$	—
Acquired noncontrolling interest in business acquisition	$	—		$	i 9,675
Acquisition of noncontrolling interest for issuance of common stock	$	i 187,500		$	—
Issuance of Series C preferred shares related to business acquisition	$	—		$	i 1,094,713

See notes to consolidated financial statements.

Healthtech Solutions, Inc./UT – ‘10-Q’ for 9/30/22

On: Wednesday, 11/23/22, at 3:24pm ET · For: 9/30/22 · Accession #: 1262463-22-147 · File #: 0-51012

Previous ‘10-Q’: ‘10-Q’ on 8/19/22 for 6/30/22 · Latest ‘10-Q’: This Filing

Quarterly Report — Form 10-Q

Filing Table of Contents

‘10-Q’ — Quarterly Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Schedule of recognized identified assets acquired and liabilities assumed
Consideration
Cash paid	$	i 517,432

Assets Acquired
Equipment	$	i 120,000
Patents Pending		i 137,432
Prepaid Commissions		i 260,000
Net assets acquired	$	i 517,432

Summary of shareholders equity
Class	Shares Authorized		Shares Outstanding
Common Stock, $.001 par value		i 200,000,000		i 69,965,933
Series A Preferred Stock, $.001 par value		i 156,937		i 110,520
Undesignated Preferred Stock, $.001 par value		i 1,843,163		i 0

Schedule of stock option assumptions used
Stock option assumptions
Risk-free interest rate			i 5.0% per annum
Expected dividend yield			i —
Expected volatility			i 11.0% per annum
Expected life of options (in years)			i 3 years

Summary of changes in convertible debentures
Balance at December 31, 2020	$	i 337,874
Issuance in February 2021	$	i 25,388
Change in fair value		( i 7,215	)
Balance at March 31, 2021	$	i 356,047
Change in fair value		i 2,940,950
Settlement upon exchange for Common Stock		( i 3,296,997	)
Balance at June 30, 2021		i —

Schedule of provision for income taxes
	September 30, 2022			September 30, 2021
U.S. federal statutory rate		i 21.0	%		i 21.0	%
State tax, net of federal benefit		i 5.0	%		i 5.0	%
Change in valuation allowance		( i 26.0	%)		( i 26.0	%)

Net deferred tax assets		i —			i —

Schedule of effective income tax rate reconciliation
U.S. federal statutory rate	i 21.0	%
State tax, net of federal benefit	i 5.0	%
Change in valuation allowance	i 26.0	%

Effective income tax rate	i —	%

Schedule of deferred tax assets
	September 30, 2022			December 31, 2021

Net operating loss carryforwards	$	i 3,167,125		$	i 2,742,460
Valuation allowance		( i 3,167,125	)		( i 2,742,460	)
Net deferred tax assets		—		$	—

		·	$367,144 in interest expense due to accretion of the debenture discount; and

		·	A loss of $2,933,735 due to an increase in the fair value of derivative liabilities, related to the 7% Convertible Debentures.

		●	Our determination to record $60,000 as the fair value of the 5.5% interest in Varian Biopharmaceuticals, Inc. that we received in November 2021. This determination was based on the financial condition of Varian Biopharmaceuticals at that time and the absence of objective criteria for attributing fair value to its technology. The fair value of Varian Biopharmaceuticals is included in the item on our Balance Sheets titled “Investment in and advance to non-consolidated affiliate.”
		●	Our determination to record an allowance of $257,432 with respect to the book value of the $517,432 prepaid commission that we advanced to Predictive Technology Group, Inc. (“PTG”) in connection with our purchase of the wound care business carried on by PTG’s subsidiary, Predictive Biotech, Inc. (See: Note 6 to the Consolidated Financial Statements.) Our determination was based on the fact that the prepaid commissions will be earned by PTG only as a result of sales to three specific customers and the fact that at the time of the acquisition Predictive Biotech, Inc. did not have a marketable product.
		●	Our determination to record an allowance for bad debt totaling five percent of the gross revenue from sales of allografts. The determination was based on industry norms, as we have experienced only one month of sales.

Item 1.	Legal Proceedings
	None.

Item 1A	Risk Factors
	There has been no change from the risk factors described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 2	Unregistered Sale of Securities and Use of Proceeds
	(a) Unregistered sales of equity securities
	On September 6, 2022 the Company issued 500,000 shares of common stock to three individuals in compensation for consulting services provided to the Company. The shares were valued at $.20 per share. The shares were issued in a private offering to investors who were acquiring the shares for their own accounts. The offering, therefore, was exempt from registration under the Securities Act of 1933 pursuant to Section 4(a)(2) of the Securities Act. On September 13, 2022 the Company issued a total of 2,500,000 shares of common stock to two entities. The shares were issued in satisfaction of payment due for consulting services rendered and in exchange for 19.99% of the outstanding capital stock of Medi-Scan, Inc. The shares were valued at $.19 per share. The shares were issued in a private offering to investors that were acquiring the shares for their own accounts. The offering, therefore, was exempt from registration under the Securities Act of 1933 pursuant to Section 4(a)(2) of the Securities Act. Except as noted above, there were no unregistered sales of equity securities by the Company during the third quarter of fiscal year 2022, other than those reported in Current Reports on Form 8-K.

	(c) Purchases of equity securities
	The Company did not repurchase any of its equity securities that were registered under Section 12 of the Securities Exchange Act during the third quarter of fiscal year 2022.

Item 3.	Defaults Upon Senior Securities.
	None.

Item 4.	Mine Safety Disclosures.
	Not Applicable.

Item 5.	Other Information.
	None.

Item 6.	Exhibits
	31-a	Rule 13a-14(a) Certification of CEO and CFO
	32-a	Rule 13a-14(b) Certification of CEO and CFO
	101.INS	Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document
	101.SCH	Inline XBRL Schema
	101.CAL	Inline XBRL Calculation
	101.DEF	Inline XBRL Definition
	101.LAB	Inline XBRL Label
	101.PRE	Inline XBRL Presentation
	104	Cover page formatted as Inline XBRL and contained in Exhibit 101

	HEALTHTECH SOLUTIONS, INC.

Date: November 23, 2022	By: /s/ *Manuel Iglesias* Manuel Iglesias, Chief Executive, Financial and Accounting Officer

This ‘10-Q’ Filing	Date	Other Filings

	5/31/24
	1/31/24
	5/4/23
Filed on:	11/23/22
For Period end:	9/30/22	NT 10-Q
	9/13/22
	9/6/22	8-K
	6/30/22	10-Q, NT 10-Q
	4/15/22	10-K
	3/31/22	10-Q, NT 10-K, NT 10-Q
	1/31/22	8-K
	1/18/22	8-K
	12/31/21	10-K, NT 10-K
	11/12/21	8-K
	11/9/21	8-K
	9/30/21	10-Q, NT 10-Q
	7/19/21	8-K
	6/30/21	10-Q, 10-Q/A, 8-K, NT 10-Q
	5/7/21
	5/6/21	8-K, 8-K/A
	5/4/21
	4/24/21	8-K
	3/31/21	10-Q, 8-K, NT 10-Q
	2/4/21
	1/31/21
	12/31/20	10-K
	11/16/20	8-K
	11/12/20	8-K
	9/25/18
		List all Filings